Evidence map›Paper›PMID 31430284›Full record

ArticlePLoS neglected tropical diseases2019

Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis.

Theresa B Gallagher, Gabriela Mellado-Sanchez, Ana L Jorgensen, Stephen Moore, James P Nataro, Marcela F Pasetti, Les W Baillie

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Plague vaccines: new developments in an ongoing search.Applied microbiology and biotechnology · 2021
    Review
  7. Vaccines · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Theresa B GallagherCenter for Vaccine Development and Global Health, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Gabriela Mellado-SanchezCenter for Vaccine Development and Global Health, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, United States of America.ORCID 0000-0002-8299-5958
Ana L JorgensenCenter for Vaccine Development and Global Health, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Stephen MooreBIOMET, University of Maryland School of Medicine, Baltimore, MD, United States of America.ORCID 0000-0001-6166-7317
James P NataroDepartment of Pediatrics, University of Virginia School of Medicine, Box, Charlottesville, VA, United States of America.
Marcela F PasettiCenter for Vaccine Development and Global Health, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Les W BaillieThe Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom.
University of Maryland, Baltimore · USCardiff University · GBUniversity of Virginia · US

Funding

Live Vector Vaccines Against Agents of BioterrorU19AI056578 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI NATARO, JAMES P. · 2003 to 2007
$8.2M
NIAID NIH HHS U19 AI056578
6 · The paper itself

Abstract

Bacillus anthracis and Yersinia pestis are zoonotic bacteria capable of causing severe and sometimes fatal infections in animals and humans. Although considered as diseases of antiquity in industrialized countries due to animal and public health improvements, they remain endemic in vast regions of the world disproportionally affecting the poor. These pathogens also remain a serious threat if deployed in biological warfare. A single vaccine capable of stimulating rapid protection against both pathogens would be an extremely advantageous public health tool. We produced multiple-antigen fusion proteins (MaF1 and MaF2) containing protective regions from B. anthracis protective antigen (PA) and lethal factor (LF), and from Y. pestis V antigen (LcrV) and fraction 1 (F1) capsule. The MaF2 sequence was also expressed from a plasmid construct (pDNA-MaF2). Immunogenicity and protective efficacy were investigated in mice following homologous and heterologous prime-boost immunization. Antibody responses were determined by ELISA and anthrax toxin neutralization assay. Vaccine efficacy was determined against lethal challenge with either anthrax toxin or Y. pestis. Both constructs elicited LcrV and LF-specific serum IgG, and MaF2 elicited toxin-neutralizing antibodies. Immunizations with MaF2 conferred 100% and 88% protection against Y. pestis and anthrax toxin, respectively. In contrast, pDNA-MaF2 conferred only 63% protection against Y. pestis and no protection against anthrax toxin challenge. pDNA-MaF2-prime MaF2-boost induced 75% protection against Y. pestis and 25% protection against anthrax toxin. Protection was increased by the molecular adjuvant CARDif. In conclusion, MaF2 is a promising multi-antigen vaccine candidate against anthrax and plague that warrants further investigation.

Indexed as

AnimalsAnthraxAntibodies, BacterialAntigens, BacterialBacillus anthracisBacterial ToxinsBacterial VaccinesDisease Models, AnimalFemaleMice, Inbred BALB CPlaguePore Forming Cytotoxic ProteinsRecombinant Fusion ProteinsSurvival AnalysisTreatment OutcomeVaccines, Syntheticanthrax toxinAntibodies, BacterialAntigens, BacterialBacterial ToxinsBacterial VaccinesLcrV protein, YersiniaPore Forming Cytotoxic ProteinsRecombinant Fusion ProteinsVaccines, Synthetic

Identifiers

PMID31430284
PMCPMC6716679
OpenAlexW2969291534

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.